Extensive data points toward the fact that patients with higher-affinity FCGR2A-p.166His or FCGR3A-p.176Val alleles have an enhanced response to monoclonal antibody-mediated anti-cancer therapy amongst solid tumors of the breast, head and neck, colorectal carcinomas as well as lymphomas (Table 3). The gene discussed is FCGR2A; the disease is cancer.